Compare Centene Corp (CNC) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Centene Corp vs Novo Nordisk A/S — how do they compare? Centene Corp trades at $66.57 (market cap $32.05B), while Novo Nordisk A/S trades at $46.18 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 6.5× Centene Corp's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Centene Corp pays none. Which is the better fit depends on your goals.
| CNC | NVO | |
|---|---|---|
Market Cap | $32.05B | $207.85B |
Sector | Health | Health |
52-Week High | $68.72 | $63.98 |
52-Week Low | $26.17 | $35.29 |
Enterprise Value | $21.10B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Centene (CNC) trades at $66.94, up 0.57% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat estimates with EPS of $2.51 versus $1.09 expected, driven by margin recovery and cost control. The stock shows attractive valuation metrics, including a P/E of 8.06 and P/S of 0.16, while revenue growth remains robust at $194.78B in 2025.
Outlook is positive with a consensus price target of $71.00, though risks include Medicaid membership volatility and net income margin pressure. The company's raised 2026 EPS guidance and operational cash flow strength support upside potential, but investors should weigh competitive and regulatory challenges in the managed care sector.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Centene Corp
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
Read more on CNC →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
